Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia

Abstract The intravenous infusion of 1‐deamino‐8‐D‐arginine vasopressin (DDAVP) is used as a nontransfusional form of treatment in patients with congenital and acquired bleeding disorders, including patients with uremia associated with prolonged bleeding times. Since uremic patients experience minor bleeding episodes that might be self‐managed at home (particularly epistaxis, gingival bleeding, and menorrhagia), we carried out a double‐blind, placebo‐controlled crossover study in nine uremics to evaluate whether the prolonged bleeding times could be shortened by subcutaneous injections of DDAVP. One hour after administration, the bleeding time was significantly shortened ( P < .01) and became normal in seven of nine patients. After 4 hr, the bleeding time was still shorter than baseline ( P < .01), but in only three patients was it still normal. There was no significant bleeding time change after placebo. When the same patients were treated with the same dose of DDAVP infused intravenously, the bleeding times were not significantly different from those measured after subcutaneous administration. Hence, subcutaneous DDAVP is an alternative method for short‐term shortening of the bleeding time in uremia, at least as effective as intravenous DDAVP but with the possibility of self‐administration by the patients at home.